For more than two decades, Annexin A6 (ANXA6) has drawn considerable interest as a potential suppressor or promoter of cancer initiation and progression in diverse cancers. Nowadays, Creative Biolabs offers ANXA6 biomarker analysis services for global clients armed with rich experience in detection and quantitation of biomarkers in a wide variety of matrices.
Background
ANXA6 belongs to a family of calcium-dependent membrane and phospholipid binding proteins. It has been implicated in mediating the endosome aggregation and vesicle fusion in secreting epithelia during exocytosis. Alternatively, spliced transcript variants have been identified. ANXA6 is closely associated with a variety of tumors. Cancer-associated fibroblast-derived ANXA6+ extracellular vesicles support pancreatic cancer aggressiveness.
Fig.1 ANXA6 involved signaling pathways.1
The dysregulation of ANXA6 has been demonstrated to be involved in different cancers as indicated in Figure 2. Thus, ANXA6 may be a potential biomarker for the diagnosis, treatment, and prognosis of certain tumors. However, the precise role of ANXA6 in drug resistance remains incomplete.
Biomarker Research to the Next Level?
Creative Biolabs validates all antibodies on WB, IHC, ICC, IF and ELISA with known positive and negative samples to ensure specificity and high affinity. We have developed ELISA assay for human/mouse/bovine/rat ANXA6 detection. Our ANXA6 services can be adapted to your specific requirements:
Our ANXA6-targeting analysis services include but not limited to the following:
| Cat | Service |
|---|---|
| BAS100-1 | ANXA6 Expression Analysis |
| BAS100-2 | Tandem Mass Tag Quantitative Proteomic Analysis |
| BAS100-3 | ANXA6 Knockdown Assay |
| BAS100-4 | Construction of ANXA6-knockdown Cell Line |
| BAS100-5 | Construction of ANXA6-overexpressing Cell Line |
| BAS100-6 | Exosomal ANXA6 Detection |
| BAS100-7 | Nucleotide-Binding Characteristic Analysis of ANXA6 |
At Creative Biolabs, we work with clients to develop assays for a wide range of biomarkers and sample types, with emphasis on in vivo disease biomarker diagnosis. If you are interested in our services, please don't hesitate to contact us today to develop custom solution for specific needs. We will work to accommodate your request.
Reference
- Cao, Jinlong, et al. "ANXA6: a key molecular player in cancer progression and drug resistance." Discover Oncology 14.1 (2023): 53. Distributed under CC BY-SA 4.0, without modification.
For Research Use Only.
